Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/31586
Title: PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: Results of a multicenter prospective study.
Authors: Gunawardana D.H.;Scott A.M.;Fulham M.J.;Ramshaw J.E.;Byrne A.J.;Stuckey J.G.;Kelley B.
Institution: (Scott, Gunawardana, Byrne) Centre for PET, Austin Hospital, Melbourne, VIC, Australia (Scott) Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, VIC, Australia (Kelley) Southern X-Ray Clinics, Wesley Hospital, Brisbane, QLD, Australia (Stuckey) MIA, Monash Medical Centre-Moorabbin Campus, Melbourne, VIC, Australia (Ramshaw) Australian and New Zealand Association of Physicians in Nuclear Medicine, Melbourne, VIC, Australia (Fulham) Department of PET and Nuclear Medicine, School of Information Technologies, University of Sydney, Sydney, NSW, Australia (Scott) Centre for PET, Austin Hospital, Studley Rd., Heidelberg, VIC 3084, Australia
Issue Date: 17-Oct-2012
Copyright year: 2008
Publisher: Society of Nuclear Medicine Inc. (1850 Samuel Morse Drive, Reston VA 22090-5316, United States)
Place of publication: United States
Publication information: Journal of Nuclear Medicine. 49 (9) (pp 1451-1457), 2008. Date of Publication: 01 Sep 2008.
Abstract: The aims of our study were to examine the impact of PET in changing management in patients with proven or suspected colorectal cancer recurrence and to assess the impact of management change on disease-free survival. Method(s): Symptomatic patients with a residual structural lesion suggestive of recurrent tumor (group A) or patients with pulmonary or hepatic metastases considered to be potentially resectable (group B) underwent PET scans. Pre-PET management plans were documented by referring clinicians unaware of the PET results, and follow-up to 12 mo was performed to determine actual management and clinical outcomes. Result(s): A total of 191 patients (118 men and 73 women; mean age, 66 y) were studied. PET detected additional sites of disease in 48.4% of patients in group A and in 43.9% of patients in group B. A change in planned management was documented in 65.6% of group A and in 49.0% of group B patients. These management plans were implemented in 96% of patients. Follow-up data in group A showed progressive disease in 60.5% of patients with additional lesions detected by PET, compared with conventional imaging, and in 36.2% of patients with no additional lesions detected by PET (P = 0.04). In group B, progressive disease was identified in 65.9%of patients with additional lesions detected by PET and in 39.2% of patients with no additional lesions detected by PET (P = 0.01). PET also provided valuable prognostic information on patients stratified into curative- or palliative-intent groups. Conclusion(s): These data demonstrate the significant impact of PET on management and outcomes in patients with suspected recurrent colorectal cancer. Copyright © 2008 by the Society of Nuclear Medicine, Inc.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.2967/jnumed.108.051615
PubMed URL: 18703607 [http://www.ncbi.nlm.nih.gov/pubmed/?term=18703607]
ISSN: 0161-5505
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/31586
Type: Article
Appears in Collections:Articles

Show full item record

Page view(s)

16
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.